• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Trial Enrollment Completion Change The Bull Case For Nipro Stock (TSE:8086)?

    Simply Wall St·10/08/2026 06:19:45
    Listen to the news
    • Nipro Corporation reported that its U.S. arm, Nipro Vascular Innovations Americas, has finished enrolling 158 patients in the GREAT pivotal trial of the investigational Golazo Peripheral Atherectomy System for symptomatic lower-extremity peripheral artery disease, a step that supports a planned 510(k) submission to the U.S. FDA.
    • This clinical milestone highlights Nipro's push to broaden its vascular device portfolio in the U.S., where atherectomy tools can matter for treating complex plaque that is less suited to standard balloon angioplasty and stent procedures.
    • We will now look at how Nipro's investment narrative could be shaped by the completion of enrollment in the GREAT Golazo atherectomy trial.

    Scan other vascular and medtech players pushing device pipelines forward with the curated 10 healthcare AI stocks to see how Nipro's Golazo trial fits into the broader treatment toolkit story.

    What Is Nipro's Investment Narrative?

    Nipro presents a broad, cash generative healthcare platform where dialysis, hospital supplies and pharma packaging carry the financial weight, while more specialized cardiovascular devices add optionality. The GREAT Golazo trial fits that second bucket. Completion of enrollment is a clean execution signal that keeps the 510(k) timeline moving, although the immediate impact on a ¥223.9b group with ¥668.9b in revenue is limited for now.

    In the near term, the bigger swing factors remain familiar. Earnings are forecast to grow 12% per year and the stock trades on a 15.9x P/E with recent returns down 9.6% year to date. However, debt coverage by operating cash flow, a dividend not well backed by free cash and recent one off items in profit all keep attention on cash discipline and capital intensity as Nipro pushes deeper into U.S. devices.

    Even so, there is one operational weak spot that could matter far more than the Golazo headline if conditions shift...

    There's only one way to know the right time to buy, sell or hold Nipro. Head to Simply Wall St's company report for the latest analysis of Nipro's Fair Value.

    TSE:8086 1-Year Stock Price Chart
    TSE:8086 1-Year Stock Price Chart

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Nipro?

    If Nipro has sharpened your thinking on medical technology, it can help to compare it with other opportunities that fit specific goals on quality, value, or income. The Simply Wall St Screener is built for exactly that kind of targeted search.

    • For investors who care most about resilience and capital protection, start with a curated set of companies screened as 22 resilient stocks with low risk scores and see which ones match your risk tolerance.
    • If balance sheet strength is a priority, focus on businesses in the list of solid balance sheet and fundamentals (23 results) to find candidates with financial structures that may better handle industry shocks.
    • Those hunting for income ideas can use the 28 dividend fortresses to quickly surface higher yield opportunities and then apply their own filters around sector, size, and country.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.